---
title: "44080.HK (44080.HK) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/44080.HK/news.md"
symbol: "44080.HK"
name: "44080.HK"
parent: "https://longbridge.com/en/quote/44080.HK.md"
datetime: "2026-03-18T07:50:47.079Z"
locales:
  - [en](https://longbridge.com/en/quote/44080.HK/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/44080.HK/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/44080.HK/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/44080.HK/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/44080.HK/news.md)


# 44080.HK (44080.HK) — Related News

### [Clover Biopharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Dividend](https://longbridge.com/en/news/279032574.md)
*2026-03-13T11:10:33.000Z*
> Clover Biopharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Dividend

### [Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor](https://longbridge.com/en/news/278866506.md)
*2026-03-12T10:45:41.000Z*
> Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

### [China National Pharmaceutical Group: TQB3454 "IDH1 Inhibitor" Phase III Clinical Study for Biliary Tract Cancer Achieves Positive Results](https://longbridge.com/en/news/278853024.md)
*2026-03-12T09:07:00.000Z*
> China National Pharmaceutical Group announced that its subsidiary, Chengda Tianqing Pharmaceutical, has achieved positiv

### [Sino Biopharmaceutical says TQB3205 pan-Kras inhibitor receives NMPA clinical trial approval](https://longbridge.com/en/news/278758513.md)
*2026-03-11T17:10:44.000Z*
> Sino Biopharmaceutical says TQB3205 pan-Kras inhibitor receives NMPA clinical trial approval

### [Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals](https://longbridge.com/en/news/277725196.md)
*2026-03-04T04:53:18.000Z*
> Shares of Antengene Corp and Sino Biopharmaceutical rose following new licensing agreements with European firms. Antenge

### [Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder](https://longbridge.com/en/news/276747729.md)
*2026-02-24T14:00:00.000Z*
> Sanyou Biopharmaceuticals has announced a significant equity restructuring, with Shanghai Liferiver Biotechnology increa

### [Shenzhen Salubris submits listing application to Hong Kong stock exchange](https://longbridge.com/en/news/275832059.md)
*2026-02-13T01:16:05.000Z*
> Shenzhen Salubris submits listing application to Hong Kong stock exchange

### [China National Pharmaceutical Group's treatment for gastric cancer, Weike Tuobai monoclonal antibody, has completed the enrollment of participants in Phase III clinical trials](https://longbridge.com/en/news/275241767.md)
*2026-02-08T23:56:00.000Z*
> China National Pharmaceutical Group announced that its self-developed antibody-drug conjugate, Weiteketuobai monoclonal 

### [Biomica Secures Global License Deal for Microbiome Cancer Therapeutic](https://longbridge.com/en/news/274817358.md)
*2026-02-04T13:02:05.000Z*